{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:38:12Z","timestamp":1769585892402,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T00:00:00Z","timestamp":1320969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s10549-011-1849-8","type":"journal-article","created":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T06:11:14Z","timestamp":1320905474000},"page":"699-708","source":"Crossref","is-referenced-by-count":17,"title":["The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms"],"prefix":"10.1007","volume":"131","author":[{"given":"Victoria K.","family":"Shanmugam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Elston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra J.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Eng-Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,11]]},"reference":[{"issue":"9324","key":"1849_CR1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M, Cuzick J, Forbes J, Houghton J, Klijn J, Sahmoud T (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324):2131\u20132139","journal-title":"Lancet"},{"issue":"9453","key":"1849_CR2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes J, Hoctin-Boes G, Houghton J, Locker G, Tobias J (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5\u00a0years\u2019 adjuvant treatment for breast cancer. Lancet 365(9453):60\u201362","journal-title":"Lancet"},{"issue":"11","key":"1849_CR3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081\u20131092. doi: 10.1056\/NEJMoa040331","journal-title":"N Engl J Med"},{"issue":"19","key":"1849_CR4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793\u20131802. doi: 10.1056\/NEJMoa032312","journal-title":"N Engl J Med"},{"issue":"3","key":"1849_CR5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"EP Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619\u2013629. doi: 10.1200\/jco.2005.09.121","journal-title":"J Clin Oncol"},{"issue":"23","key":"1849_CR6","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","volume":"28","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer. J Clin Oncol 28(23):3784\u20133796. doi: 10.1200\/jco.2009.26.3756","journal-title":"J Clin Oncol"},{"issue":"3","key":"1849_CR7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.breast.2007.01.011","volume":"16","author":"HJ Burstein","year":"2007","unstructured":"Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. The Breast 16(3):223\u2013234","journal-title":"The Breast"},{"issue":"3","key":"1849_CR8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2007.10.004","volume":"34","author":"RE Coleman","year":"2008","unstructured":"Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275\u2013282","journal-title":"Cancer Treat Rev"},{"issue":"25","key":"1849_CR9","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1200\/JCO.2007.11.9529","volume":"25","author":"HJ Burstein","year":"2007","unstructured":"Burstein HJ, Winer EP (2007) Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 25(25):3797\u20133799. doi: 10.1200\/jco.2007.11.9529","journal-title":"J Clin Oncol"},{"issue":"1","key":"1849_CR10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-006-9394-6","volume":"104","author":"L Morales","year":"2007","unstructured":"Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Van Limbergen E, Weltens C, Van den Bogaert W, De Smet L, Vergote I, Christiaens M, Neven P (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104(1):87\u201391","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"1849_CR11","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1002\/cncr.25385","volume":"116","author":"N Henry","year":"2010","unstructured":"Henry N, Jacobson J, Banerjee M, Hayden J, Smerage J, Van Poznak C, Storniolo A, Stearns V, Hayes D (2010) A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer 116(18):4360\u20134367. doi: 10.1002\/cncr.25385","journal-title":"Cancer"},{"key":"1849_CR12","doi-asserted-by":"crossref","unstructured":"Henry NL, Pchejetski D, A\u2019Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, Hayes DF, Flockhart DA, Stearns V, Stebbing J (2010) Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer 103(3):291\u2013296. doi: http:\/\/www.nature.com\/bjc\/journal\/v103\/n3\/suppinfo\/6605768s1.html","DOI":"10.1038\/sj.bjc.6605768"},{"issue":"8","key":"1849_CR13","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/annonc\/mdq699","volume":"22","author":"A Lintermans","year":"2011","unstructured":"Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonn\u00e9 AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P (2011) Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 22(8):1763\u20131769. doi: 10.1093\/annonc\/mdq699","journal-title":"Ann Oncol"},{"issue":"3","key":"1849_CR14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1188\/10.CJON.379-382","volume":"14","author":"L Winters","year":"2010","unstructured":"Winters L, Habin K, Flanagan J, Cashavelly B (2010) I feel like i am 100 years old! Managing arthralgias from aromatase inhibitors. Clin J Oncol Nurs 14(3):379\u2013382","journal-title":"Clin J Oncol Nurs"},{"issue":"30","key":"1849_CR15","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1200\/JCO.2008.20.5435","volume":"27","author":"O Dizdar","year":"2009","unstructured":"Dizdar O, Ozcakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S, Ozisik Y, Altundag K (2009) Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 27(30):4955\u20134960. doi: 10.1200\/jco.2008.20.5435","journal-title":"J Clin Oncol"},{"issue":"16","key":"1849_CR16","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.24419","volume":"115","author":"JJ Mao","year":"2009","unstructured":"Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16):3631\u20133639. doi: 10.1002\/cncr.24419","journal-title":"Cancer"},{"issue":"25","key":"1849_CR17","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2007.10.7573","volume":"25","author":"KD Crew","year":"2007","unstructured":"Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877\u20133883. doi: 10.1200\/jco.2007.10.7573","journal-title":"J Clin Oncol"},{"issue":"12","key":"1849_CR18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","volume":"9","author":"J Cuzick","year":"2008","unstructured":"Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143\u20131148. doi: 10.1016\/s1470-2045(08)70259-6","journal-title":"Lancet Oncol"},{"issue":"2","key":"1849_CR19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-007-9774-6","volume":"111","author":"N Henry","year":"2008","unstructured":"Henry N, Giles J, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes D, Storniolo AM, Clauw D (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365\u2013372. doi: 10.1007\/s10549-007-9774-6","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"1849_CR20","first-page":"2259","volume":"34","author":"M Laroche","year":"2007","unstructured":"Laroche M, Borg S, Lassoued S, De Lafontan B, Roch\u00e9 H (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sj\u00f6gren\u2019s syndrome. J Rheumatol 34(11):2259\u20132263","journal-title":"J Rheumatol"},{"issue":"2","key":"1849_CR21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3816\/CBC.2010.n.019","volume":"10","author":"G Moxley","year":"2010","unstructured":"Moxley G (2010) Rheumatic disorders and functional disability with aromatase inhibitor therapy. Clin Breast Cancer 10(2):144\u2013147","journal-title":"Clin Breast Cancer"},{"issue":"19","key":"1849_CR22","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1200\/JCO.2007.15.4005","volume":"26","author":"L Morales","year":"2008","unstructured":"Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens M-R, Neven P (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19):3147\u20133152. doi: 10.1200\/jco.2007.15.4005","journal-title":"J Clin Oncol"},{"issue":"9","key":"1849_CR23","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/art.21364","volume":"52","author":"DT Felson","year":"2005","unstructured":"Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52(9):2594\u20132598","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1849_CR24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.1780340819","volume":"34","author":"I Kushner","year":"1991","unstructured":"Kushner I (1991) C-reactive protein in rheumatology. Arthritis Rheum 34(8):1065\u20131068","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1849_CR25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/rheumatology\/32.7.589","volume":"32","author":"M Prevoo","year":"1993","unstructured":"Prevoo M, Van Riel P, Van \u2018T Hof M, Van Rijswijk M, Van Leeuwen M, Kuper H, Van De Putte L (1993) Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol 32(7):589\u2013594","journal-title":"Br J Rheumatol"},{"issue":"3","key":"1849_CR26","first-page":"216","volume":"66","author":"T Pincus","year":"2008","unstructured":"Pincus T (2008) Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid. Arthritis Bull NYU Hosp Joint Dis 66(3):216\u2013223","journal-title":"Arthritis Bull NYU Hosp Joint Dis"},{"issue":"11","key":"1849_CR27","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780331101","volume":"33","author":"R Altman","year":"1990","unstructured":"Altman R, Alarc\u00f3n G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke T, Daniel W, Gray R (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33(11):1601\u20131610","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1849_CR28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","volume":"33","author":"F Wolfe","year":"1990","unstructured":"Wolfe F, Smythe H, Yunus M, Bennett R, Bombardier C, Goldenberg D, Tugwell P, Campbell S, Abeles M, Clark P (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33(2):160\u2013172","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1849_CR29","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. doi: 10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1849_CR30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"F Arnett","year":"1988","unstructured":"Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, Healey L, Kaplan S, Liang M, Luthra H, Medsger T, Mitchell D, Neustadt D, Pinals R, Schaller J, Sharp J, Wilder R, Hunder G (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1849_CR31","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202\u2013205","journal-title":"J Rheumatol"},{"issue":"7","key":"1849_CR32","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573\u20131576","journal-title":"J Rheumatol"},{"issue":"5","key":"1849_CR33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.1780290501","volume":"29","author":"R Fox","year":"1986","unstructured":"Fox R, Robinson C, Curd J, Kozin F, Howell F (1986) Sj\u00f6gren\u2019s syndrome. Proposed criteria for classification. Arthritis Rheum 29(5):577\u2013585","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1849_CR34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554\u2013558","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1849_CR35","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3899\/jrheum.090358","volume":"36","author":"J Fries","year":"2009","unstructured":"Fries J, Cella D, Rose M, Krishnan E, Bruce B (2009) Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol 36(9):2061\u20132066. doi: 10.3899\/jrheum.090358","journal-title":"J Rheumatol"},{"issue":"11","key":"1849_CR36","first-page":"2324","volume":"26","author":"H Paulus","year":"1999","unstructured":"Paulus H, Ramos B, Wong W, Ahmed A, Bulpitt K, Park G, Sterz M, Clements P (1999) Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the disease activity score in patients with early rheumatoid arthritis. Western consortium of practicing rheumatologists. J Rheumatol 26(11):2324\u20132331","journal-title":"J Rheumatol"},{"issue":"8","key":"1849_CR37","first-page":"1477","volume":"24","author":"F Wolfe","year":"1997","unstructured":"Wolfe F (1997) Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 24(8):1477\u20131485","journal-title":"J Rheumatol"},{"issue":"47","key":"1849_CR38","doi-asserted-by":"crossref","first-page":"48487","DOI":"10.1074\/jbc.R400025200","volume":"279","author":"S Black","year":"2004","unstructured":"Black S, Kushner I, Samols D (2004) C-reactive protein. J Biol Chem 279(47):48487\u201348490. doi: 10.1074\/jbc.R400025200","journal-title":"J Biol Chem"},{"issue":"4","key":"1849_CR39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/ard.59.4.289","volume":"59","author":"S Kessler","year":"2000","unstructured":"Kessler S, Dieppe P, Fuchs J, St\u00fcrmer T, G\u00fcnther KP (2000) Assessing the prevalence of hand osteoarthritis in epidemiological studies. The reliability of a radiological hand scale. Ann Rheum Dis 59(4):289\u2013292. doi: 10.1136\/ard.59.4.289","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1849_CR40","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1136\/ard.2004.034371","volume":"64","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Klareskog L, Boers M, Landew\u00e9 R, Codreanu C, Bolosiu HD, Pedersen R, Fatenejad S (2005) Comparison of different definitions to classify remission and sustained remission: 1\u00a0year TEMPO results. Ann Rheum Dis 64(11):1582\u20131587. doi: 10.1136\/ard.2004.034371","journal-title":"Ann Rheum Dis"},{"key":"1849_CR41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0093-7754(03)00305-1","volume":"14","author":"P L\u00f8nning","year":"2003","unstructured":"L\u00f8nning P, Pfister C, Martoni A, Zamagni C (2003) Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol 14:23\u201332. doi: 10.1016\/s0093-7754(03)00305-1","journal-title":"Semin Oncol"},{"issue":"12","key":"1849_CR42","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1210\/jc.2003-031279","volume":"88","author":"N Mauras","year":"2003","unstructured":"Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, Lippe B (2003) Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 88(12):5951\u20135956. doi: 10.1210\/jc.2003-031279","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1849_CR43","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1200\/JCO.1993.11.6.1189","volume":"11","author":"D Waterhouse","year":"1993","unstructured":"Waterhouse D, Calzone K, Mele C, Brenner D (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189\u20131197","journal-title":"J Clin Oncol"},{"issue":"5","key":"1849_CR44","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.22485","volume":"109","author":"TI Barron","year":"2007","unstructured":"Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. Cancer 109(5):832\u2013839. doi: 10.1002\/cncr.22485","journal-title":"Cancer"},{"issue":"11","key":"1849_CR45","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","volume":"99","author":"C McCowan","year":"2008","unstructured":"McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763\u20131768","journal-title":"Br J Cancer"},{"issue":"3","key":"1849_CR46","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10549-009-0724-3","volume":"122","author":"M Herk-Sukel van","year":"2010","unstructured":"van Herk-Sukel M, van de Poll-Franse L, Voogd A, Nieuwenhuijzen G, Coebergh J, Herings R (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5\u00a0years: a population-based analysis. Breast Cancer Res Treat 122(3):843\u2013851. doi: 10.1007\/s10549-009-0724-3","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"1849_CR47","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0959-8049(02)00154-5","volume":"38","author":"M Baum","year":"2002","unstructured":"Baum M (2002) The ATAC (arimidex(TM), tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. Eur J Cancer 38(15):1984\u20131986","journal-title":"Eur J Cancer"},{"issue":"4","key":"1849_CR48","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","volume":"26","author":"AH Partridge","year":"2008","unstructured":"Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556\u2013562. doi: 10.1200\/jco.2007.11.5451","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1849-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1849-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1849-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T10:16:09Z","timestamp":1560939369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1849-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,11]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1849"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1849-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,11]]}}}